Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4971) 4971
Publication (507) 507
Book Review (92) 92
Book Chapter (53) 53
Dissertation (13) 13
Web Resource (4) 4
Conference Proceeding (3) 3
Paper (2) 2
Data Set (1) 1
Magazine Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3187) 3187
index medicus (2598) 2598
pegylated interferon (2432) 2432
ribavirin (1877) 1877
antiviral agents - therapeutic use (1860) 1860
male (1673) 1673
gastroenterology & hepatology (1640) 1640
hepatitis c (1622) 1622
female (1598) 1598
hepatitis c, chronic - drug therapy (1512) 1512
middle aged (1401) 1401
hepatitis c virus (1314) 1314
adult (1285) 1285
interferon (1238) 1238
treatment outcome (1214) 1214
interferon-alpha - therapeutic use (1200) 1200
drug therapy, combination (1038) 1038
ribavirin - therapeutic use (1035) 1035
genotype (881) 881
hepacivirus - genetics (879) 879
polyethylene glycols - therapeutic use (838) 838
virus-infection (806) 806
therapy (799) 799
sustained virological response (778) 778
recombinant proteins (749) 749
pegylated interferon-alpha-2b (741) 741
plus ribavirin (708) 708
biological response modifiers (689) 689
hepatitis (686) 686
aged (680) 680
infectious diseases (651) 651
hepatitis c - drug therapy (642) 642
antiviral agents - adverse effects (618) 618
chronic hepatitis c (599) 599
virology (592) 592
antiviral agents - administration & dosage (588) 588
infection (578) 578
pharmacology & pharmacy (577) 577
health aspects (570) 570
combination therapy (567) 567
care and treatment (555) 555
peginterferon alpha-2a (538) 538
hepatitis c, chronic - virology (535) 535
hepacivirus - drug effects (534) 534
interferon-alpha - administration & dosage (499) 499
hcv (494) 494
viral load (487) 487
ribavirin - administration & dosage (442) 442
antiviral therapy (440) 440
interferon-alpha - adverse effects (438) 438
virus diseases (431) 431
recombinant proteins - therapeutic use (427) 427
antiviral agents (421) 421
chronic hepatitis-c (420) 420
analysis (401) 401
drug therapy (398) 398
polyethylene glycols - administration & dosage (380) 380
liver (371) 371
hepatitis c, chronic - complications (367) 367
cirrhosis (362) 362
gastroenterology and hepatology (351) 351
immunology (350) 350
rna, viral - blood (349) 349
hepatocellular-carcinoma (346) 346
ribavirin - adverse effects (345) 345
hiv (334) 334
risk factors (331) 331
telaprevir (331) 331
genetic aspects (329) 329
pegylated interferon-alpha (325) 325
treatment-naive patients (309) 309
retrospective studies (304) 304
young adult (303) 303
virological response (301) 301
polyethylene glycols - adverse effects (297) 297
pegylated-interferon (296) 296
virus (296) 296
peginterferon (295) 295
randomized-trial (293) 293
medicine, general & internal (289) 289
combination (287) 287
time factors (285) 285
efficacy (284) 284
oncology (284) 284
research (276) 276
transplantation (272) 272
hepatology (266) 266
recurrence (266) 266
liver transplantation (262) 262
digestive system diseases (259) 259
hepatitis b (258) 258
hiv infections - complications (258) 258
peginterferon alpha-2b (258) 258
genotype 1 infection (257) 257
interferon-alpha-2b plus ribavirin (255) 255
hepatitis c, chronic - genetics (253) 253
initial treatment (253) 253
infections (252) 252
interleukins - genetics (249) 249
hepatitis b, chronic - drug therapy (248) 248
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4613) 4613
Korean (82) 82
Spanish (73) 73
French (56) 56
German (43) 43
Japanese (36) 36
Hungarian (35) 35
Czech (22) 22
Polish (19) 19
Russian (15) 15
Turkish (11) 11
Portuguese (9) 9
Chinese (8) 8
Croatian (5) 5
Serbian (4) 4
Slovak (4) 4
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment
by Riva, E and Scagnolari, C and Turriziani, O and Antonelli, G
Clinical Microbiology and Infection, ISSN 1198-743X, 12/2014, Volume 20, Issue 12, pp. 1237 - 1245
There has been a significant increase in our understanding of the host genetic determinants of susceptibility to viral infections in recent years. Recently,... 
host genetics | interferon-λ4 | interferon-λ3 | HCV infection | single-nucleotide polymorphisms | interferon‐λ4 | single‐nucleotide polymorphisms | interferon‐λ3 | infection | HCV | Host genetics | Single-nucleotide polymorphisms | Interferon-λ4 | Interferon-λ3 | INFECTIOUS DISEASES | interferon-3 | PLUS RIBAVIRIN | interferon-4 | MICROBIOLOGY | COINFECTED PATIENTS | IL28B GENOTYPE | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HCV GENOTYPE | VIRAL CLEARANCE | GENOME-WIDE ASSOCIATION | SPONTANEOUS CLEARANCE | TREATMENT FAILURE | Hepatitis C - immunology | Interleukins - genetics | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Treatment Outcome | Interferons - genetics | Cytokines | Infections | Viral infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Southwest oncology group S0008: A Phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma-an intergroup study of cancer and leukemia group B, children's oncology group, eastern cooperative oncology group, and southwest oncology group
by Flaherty, Lawrence E and Othus, Megan and Atkins, Michael B and Tuthill, Ralph J and Thompson, John A and Vetto, John T and Haluska, Frank G and Pappo, Alberto S and Sosman, Jeffrey A and Redman, Bruce G and Moon, James and Ribas, Antoni and Kirkwood, John M and Sondak, Vernon K
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 33, pp. 3771 - 3778
Purpose High-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration-approved adjuvant therapy for patients with high-risk melanoma.... 
SURVIVAL | METASTATIC MALIGNANT-MELANOMA | METAANALYSIS | ONCOLOGY | CHEMOIMMUNOTHERAPY | RANDOMIZED-TRIAL | ALPHA | ADJUVANT THERAPY | PEGYLATED INTERFERON-ALPHA-2B | COMBINATION | CONCURRENT BIOCHEMOTHERAPY | Recombinant Proteins - therapeutic use | Dacarbazine - adverse effects | Interleukin-2 - adverse effects | Humans | Middle Aged | Interferons - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Recombinant Proteins - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Interleukin-2 - administration & dosage | Vinblastine - adverse effects | Adult | Female | Child | Dacarbazine - administration & dosage | Interferon-alpha - therapeutic use | Interferons - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Adolescent | Interferon alpha-2 | Cisplatin - adverse effects | Aged | Interferon-alpha - adverse effects | Melanoma - mortality | Index Medicus | Original Reports | Bios3 | Mela5 | To21
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ribavirin potentiates interferon action by augmenting interferon‐stimulated gene induction in hepatitis C virus cell culture models
by Thomas, Emmanuel and Feld, Jordan J and Li, Qisheng and Hu, Zongyi and Fried, Michael W and Liang, T. Jake
Hepatology, ISSN 0270-9139, 01/2011, Volume 53, Issue 1, pp. 32 - 41
The combination of pegylated interferon (PEG‐IFN) and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that... 
SUSTAINED VIROLOGICAL RESPONSE | PLUS RIBAVIRIN | RNA | PEGYLATED INTERFERON | STELLATE CELLS | ANTIVIRAL ACTIVITY | GASTROENTEROLOGY & HEPATOLOGY | PROTEASOME INHIBITORS | PEGINTERFERON | EXPRESSION | VIRAL-INFECTION | Hepacivirus - drug effects | Interferon-alpha - pharmacology | Humans | Ribavirin - therapeutic use | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Drug Synergism | Interferon-Stimulated Gene Factor 3, gamma Subunit - biosynthesis | Interferon Regulatory Factor-7 - biosynthesis | Proteins - metabolism | NF-kappa B - physiology | Guanosine - pharmacology | Hepacivirus - physiology | Tumor Cells, Cultured | Ribavirin - pharmacology | Polyethylene Glycols - pharmacology | Hepatitis | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Comparison of two PEG‐interferon alpha‐2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon‐naïve patients with chronic hepatitis C and up to moderate fibrosis
by Meyer‐Wyss, B and Rich, P and Egger, Hp and Helbling, B and Müllhaupt, B and Rammert, C and Gonvers, J.‐J and Oneta, C and Criblez, D and Rossi, L and Borovicka, J and Meyenberger, C and Arn, M and Renner, E. L and SASL and Swiss Association for the Study of the Liver (SASL)
Journal of Viral Hepatitis, ISSN 1352-0504, 07/2006, Volume 13, Issue 7, pp. 457 - 465
Health regulatory approval of the 1.5  μ g/kg body weight dose of pegylated interferon (PEG‐I) alpha‐2b in combination with ribavirin for the treatment of... 
antiviral treatment | side effects | pegylated interferon | ribavirin | hepatitis C | Side effects | Antiviral treatment | Hepatitis C | Pegylated interferon | Ribavirin | VIRUS-RELATED CIRRHOSIS | INFECTIOUS DISEASES | PLUS RIBAVIRIN | INITIAL TREATMENT | RANDOMIZED-TRIAL | COMBINATION | VIROLOGY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Liver Cirrhosis - drug therapy | Hepatitis C, Chronic - pathology | Polyethylene Glycols | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Hepatitis C, Chronic - virology | Male | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Dose-Response Relationship, Drug | Interferon-alpha - administration & dosage | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Liver Cirrhosis - pathology | Adult | Female | Aged | Interferon-alpha - adverse effects | Drug Therapy, Combination | Hepacivirus | Dosage and administration | Interferon | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
by Pawlotsky, Jean-Michel
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 1, pp. 70 - 86
Treatment of hepatitis C virus (HCV) infection has progressed considerably with the approval of interferon-free, direct-acting antiviral (DAA)-based... 
Gastroenterology and Hepatology | Resistance | Retreatment | Resistance-Associated Substitutions | Treatment Failure | BASE-LINE | DACLATASVIR PLUS ASUNAPREVIR | GRAZOPREVIR/ELBASVIR PLUS | VIROLOGICAL TOOLS | PEGYLATED INTERFERON | CLINICAL-TRIALS | GENOTYPE 1 INFECTION | TERM-FOLLOW-UP | 1-INFECTED PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Hepacivirus - drug effects | Protease Inhibitors - pharmacology | Recurrence | Antiviral Agents - pharmacology | Hepatitis C - drug therapy | Humans | Drug Resistance, Viral | Hepacivirus - genetics | Genotype | Drug Therapy, Combination | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Protease inhibitors | Proteases | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
by Ramamurthy, Narayan and Marchi, Emanuele and Ansari, M. Azim and Pedergnana, Vincent and Mclean, Angela and Hudson, Emma and Bowden, Rory and Spencer, Chris C.A and Barnes, Eleanor and Klenerman, Paul and STOP HCV Consortium and STOP HCV consortium
Hepatology, ISSN 0270-9139, 09/2018, Volume 68, Issue 3, pp. 859 - 871
New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been... 
HCV RNA | PLUS RIBAVIRIN | R/BIOCONDUCTOR PACKAGE | VIRUS | SOFOSBUVIR | PEGYLATED INTERFERON | IL28B GENOTYPE | RIBAVIRIN THERAPY | GASTROENTEROLOGY & HEPATOLOGY | PEGINTERFERON | SPONTANEOUS CLEARANCE | Cirrhosis | Genotype & phenotype | Hepatitis | Phenotypes | Liver | Peripheral blood | Interferon | Gene expression | Hepatitis C | Genotypes | Ribavirin | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Interferon-λpolymorphisms and response to pegylated interferon in Iranian hepatitis C patients
by Haj-sheykholeslami, Arghavan and Keshvari, Maryam and Sharafi, Heidar and Pouryasin, Ali and Hemmati, Khalil and Mohammadzadehparjikolaei, Fatemeh
World Journal of Gastroenterology, ISSN 1007-9327, 08/2015, Volume 21, Issue 29, pp. 8848 - 8857
To evaluate the efficacy of pegylated interferon in Iranian chronic hepatitis C patients in relation to interferon-λ (IFNL) polymorphisms. This study enrolled... 
Sustained virologic response? | Rs8099917 | Rs12979860 | Chronic hepatitis C | Pegylated interferon | Recombinant Proteins - therapeutic use | Multivariate Analysis | Prospective Studies | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | Viral Load | Interleukins - genetics | Iran | Adult | Female | Drug Therapy, Combination | Odds Ratio | Hepacivirus - drug effects | Pharmacogenetics | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Phenotype | Hepatitis C, Chronic - immunology | Polymorphism, Single Nucleotide | Hepatitis C, Chronic - genetics | Prospective Study | rs12979860 | rs8099917 | Sustained virologic response
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis
by Udina, Marc and Castellví, Pere and Moreno-España, José and Navinés, Ricard and Valdés, Manuel and Forns, Xavier and Langohr, Klaus and Solà, Ricard and Vieta, Eduard and Martín-Santos, Rocío
Journal of Clinical Psychiatry, ISSN 0160-6689, 2012, Volume 73, Issue 8, pp. 1128 - 1138
Objective: To carry out a systematic review of the risk factors for, and incidence of, major depressive episode (MDE) related to antiviral therapy for chronic... 
SUSTAINED VIROLOGICAL RESPONSE | PLUS RIBAVIRIN | VIRUS-INFECTION | THERAPY | PSYCHIATRY | PEGYLATED INTERFERON | INITIAL TREATMENT | QUALITY-OF-LIFE | MAJOR DEPRESSION | PSYCHOLOGY, CLINICAL | ALPHA-INDUCED DEPRESSION | IFN-ALPHA | Recombinant Proteins - therapeutic use | Prospective Studies | Cross-Sectional Studies | Antiviral Agents - therapeutic use | Humans | Risk Factors | Interferon-alpha - therapeutic use | Polyethylene Glycols - adverse effects | Recombinant Proteins - adverse effects | Hepatitis C, Chronic - drug therapy | Depressive Disorder, Major - epidemiology | Polyethylene Glycols - therapeutic use | Incidence | Depressive Disorder, Major - chemically induced | Depressive Disorder, Major - psychology | Antiviral Agents - adverse effects | Female | Interferon-alpha - adverse effects | Depressive Disorder, Major - diagnosis | Hepatitis C, Chronic - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Anti‐interferon‐α neutralizing antibody is associated with nonresponse to pegylated interferon‐α plus ribavirin in chronic hepatitis C
by Matsuda, F and Torii, Y and Enomoto, H and Kuga, C and Aizawa, N and Iwata, Y and Saito, M and Imanishi, H and Shimomura, S and Nakamura, H and Tanaka, H and Iijima, H and Tsutsui, H and Tanaka, Y and Nishiguchi, S
Journal of Viral Hepatitis, ISSN 1352-0504, 10/2012, Volume 19, Issue 10, pp. 694 - 703
Pegylated interferon‐α (PEG‐IFN‐α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20–50% of patients... 
anti‐interferon‐α neutralizing antibody | nonresponse | natural interferon‐β | chronic hepatitis C | pegylated interferon‐α | pegylated interferon-α | anti-interferon-α neutralizing antibody | natural interferon-β | Humans | Middle Aged | Male | Neutralization Tests | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Interferon-alpha - immunology | Interferon-alpha - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Aged | Antibodies, Neutralizing - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text HCV direct‐acting antiviral agents: the best interferon‐free combinations
by Schinazi, Raymond and Halfon, Philippe and Marcellin, Patrick and Asselah, Tarik
Liver International, ISSN 1478-3223, 02/2014, Volume 34, Issue 1, pp. 69 - 78
For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct‐acting antivirals (... 
sofosbuvir | faldaprevir | ribavirin | simeprevir | pegylated interferon | asunaprevir | daclatasvir | Daclatasvir | Simeprevir | Pegylated interferon | Faldaprevir | Asunaprevir | Ribavirin | Sofosbuvir | BILN-2061 | TELAPREVIR | PROTEASE INHIBITOR | HEPATITIS | RESISTANCE | GASTROENTEROLOGY & HEPATOLOGY | PROGRESSION | Heterocyclic Compounds, 3-Ring | Hepatitis C - drug therapy | Oligopeptides | Isoquinolines | Humans | Hepacivirus - genetics | Drug Discovery - methods | Disease Eradication - methods | Recombinant Proteins | Protease Inhibitors - pharmacology | Thiazoles | Hepacivirus - drug effects | Virus Replication - drug effects | Antiviral Agents - pharmacology | Polyethylene Glycols | Antiviral Agents - therapeutic use | Interferon-alpha | Clinical Trials as Topic | Disease Eradication - trends | Drug Therapy, Combination - methods | Drug Therapy, Combination - trends | Imidazoles | Sulfonamides | Uridine Monophosphate - analogs & derivatives | Viral Nonstructural Proteins - antagonists & inhibitors | Virus Replication - physiology | Hepatitis C virus | Biological response modifiers | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Type I interferons in anticancer immunity
by Zitvogel, Laurence and Galluzzi, Lorenzo and Kepp, Oliver and Smyth, Mark J and Kroemer, Guido
Nature Reviews Immunology, ISSN 1474-1733, 07/2015, Volume 15, Issue 7, pp. 405 - 414
Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I... 
PLASMACYTOID DENDRITIC CELLS | HEPATOCELLULAR-CARCINOMA | STEM-CELLS | STAGE-III MELANOMA | REGULATORY T-CELLS | PEGYLATED INTERFERON-ALPHA-2B | CANCER-IMMUNOTHERAPY | IMMUNOLOGY | TUMOR MICROENVIRONMENT | CHRONIC MYELOID-LEUKEMIA | IFN-ALPHA | Immunotherapy - methods | Interferon Type I - therapeutic use | Animals | Interferon Type I - immunology | Neoplasms - immunology | Humans | Interferon | Genetic aspects | Immune response | Health aspects | Carcinogenesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights